{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:32:45Z","timestamp":1783567965614,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cholesteatoma disease is an expanding lesion in the middle ear. Hearing loss and facial paralysis alongside with other intracranial complications are found. No pharmaceutical treatment is available today and recurrence after surgical extraction occurs. We investigated possible TLR4-based mechanisms promoting recurrence and explore possible treatments strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We isolated fibroblasts and epidermal stem cells from cholesteatoma tissue and healthy auditory canal skin. Subsequently, their expression under standard culture conditions and after stimulation with LPS was investigated by RT-qPCR. Cell metabolism and proliferation were analysed upon LPS treatment, with and without TLR4 antagonist. An indirect co-culture of fibroblasts and epidermal stem cells isolated from cholesteatoma tissue was utilized to monitor epidermal differentiation upon LPS treatment by RT-qPCR and immunocytochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Under standard culture conditions, we detected a tissue-independent higher expression of IL-1\u03b2 and IL-8 in stem cells, an upregulation of KGF and IGF-2 in both cell types derived from cholesteatoma and higher expression of TLR4 in stem cells derived from cholesteatoma tissue. Upon LPS challenge, we could detect a significantly higher expression of IL-1\u03b1, IL-1\u03b2, IL-6 and IL-8 in stem cells and of TNF-a, GM-CSF and CXCL-5 in stem cells and fibroblasts derived from cholesteatoma. The expression of the growth factors KGF, EGF, EREG, IGF-2 and HGF was significantly higher in fibroblasts, particularly when derived from cholesteatoma. Upon treatment with LPS the metabolism was elevated in stem cells and fibroblasts, proliferation was only enhanced in fibroblasts derived from cholesteatoma. This could be reversed by the treatment with a TLR4 antagonist. The cholesteatoma fibroblasts could be triggered by LPS to promote the epidermal differentiation of the stem cells, while no LPS treatment or LPS treatment without the presence of fibroblasts did not result in such a differentiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We propose that cholesteatoma recurrence is based on TLR4 signalling imprinted in the cholesteatoma cells. It induces excessive inflammation of stem cells and fibroblasts, proliferation of perimatrix fibroblasts and the generation of epidermal cells from stem cells thru paracrine signalling by fibroblasts. Treatment of the operation site with a TLR4 antagonist might reduce the chance of cholesteatoma recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-020-00690-y","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T07:03:18Z","timestamp":1614150198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism"],"prefix":"10.1186","volume":"19","author":[{"given":"Matthias","family":"Sch\u00fcrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Oppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Volland-Thurn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kaltschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kaltschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Uwe","family":"Scholtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Sudhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"issue":"5","key":"690_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1080\/00016489950180801","volume":"119","author":"HO Kemppainen","year":"1999","unstructured":"Kemppainen HO, et al. Epidemiology and aetiology of middle ear cholesteatoma. Acta Otolaryngol. 1999;119(5):568\u201372.","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"690_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3109\/00016489309135826","volume":"113","author":"J Bujia","year":"1993","unstructured":"Bujia J, et al. Hyperproliferation-associated keratin expression in human middle ear cholesteatoma. Acta Otolaryngol. 1993;113(3):364\u20138.","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"690_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00405-003-0623-x","volume":"261","author":"E Olszewska","year":"2004","unstructured":"Olszewska E, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol. 2004;261(1):6\u201324.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"690_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1017\/S0022215109992763","volume":"124","author":"L Louw","year":"2010","unstructured":"Louw L. Acquired cholesteatoma pathogenesis: stepwise explanations. J Laryngol Otol. 2010;124(6):587\u201393.","journal-title":"J Laryngol Otol"},{"issue":"4","key":"690_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/0196-0709(95)90148-5","volume":"16","author":"V Schilling","year":"1995","unstructured":"Schilling V, et al. High levels of fibronectin in the stroma of aural cholesteatoma. Am J Otolaryngol. 1995;16(4):232\u20135.","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"690_CR6","first-page":"28","volume":"13","author":"M Abdelmonem","year":"2015","unstructured":"Abdelmonem M, Mostafa O. Immunohistochemical study of KI67, PCNA and P53 in human acquired cholesteatoma. AAMJ. 2015;13(4):28\u201338.","journal-title":"AAMJ"},{"issue":"11","key":"690_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1288\/00005537-199511000-00017","volume":"105","author":"H Sudhoff","year":"1995","unstructured":"Sudhoff H, et al. Expression of a cell-cycle-associated nuclear antigen (MIB 1) in cholesteatoma and auditory meatal skin. Laryngoscope. 1995;105(11):1227\u201331.","journal-title":"Laryngoscope"},{"issue":"8","key":"690_CR8","first-page":"CR337","volume":"12","author":"E Olszewska","year":"2006","unstructured":"Olszewska E, et al. Some markers of proliferative activity in cholesteatoma epithelium in adults. Med Sci Monit. 2006;12(8):CR337\u201340.","journal-title":"Med Sci Monit"},{"issue":"12","key":"690_CR9","doi-asserted-by":"publisher","first-page":"e52718","DOI":"10.1371\/journal.pone.0052718","volume":"7","author":"C Klenke","year":"2012","unstructured":"Klenke C, et al. Identification of novel cholesteatoma-related gene expression signatures using full-genome microarrays. PLoS ONE. 2012;7(12):e52718.","journal-title":"PLoS ONE"},{"issue":"S02","key":"690_CR10","first-page":"10100","volume":"97","author":"M Hamed","year":"2018","unstructured":"Hamed M, et al. Cytokeratin expression pattern in acquired cholesteatoma versus meatal skin; an immunochemical study. Laryngorhinootologie. 2018;97(S02):10100.","journal-title":"Laryngorhinootologie"},{"key":"690_CR11","first-page":"1","volume":"5","author":"H Frickmann","year":"2012","unstructured":"Frickmann H, Zautner AE. Cholesteatoma\u2013a potential consequence of chronic middle ear inflammation. Otolaryngol Spec Issue. 2012;5:1\u20138.","journal-title":"Otolaryngol Spec Issue"},{"issue":"4","key":"690_CR12","first-page":"197","volume":"29","author":"F Ricciardiello","year":"2009","unstructured":"Ricciardiello F, et al. Notes on the microbiology of cholesteatoma: clinical findings and treatment. Acta Otorhinolaryngol Ital. 2009;29(4):197\u2013202.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"16683","DOI":"10.1038\/srep16683","volume":"5","author":"Y Si","year":"2015","unstructured":"Si Y, et al. TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction. Sci Rep. 2015;5:16683.","journal-title":"Sci Rep"},{"issue":"1","key":"690_CR14","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1038\/s41598-018-24616-4","volume":"8","author":"J Nagel","year":"2018","unstructured":"Nagel J, et al. Stem cells in middle ear cholesteatoma contribute to its pathogenesis. Sci Rep. 2018;8(1):6204.","journal-title":"Sci Rep"},{"issue":"5","key":"690_CR15","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.4049\/jimmunol.174.5.2964","volume":"174","author":"D Preciado","year":"2005","unstructured":"Preciado D, et al. Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF-kappa B, and cyclin D1 is inhibited by indomethacin. J Immunol. 2005;174(5):2964\u201373.","journal-title":"J Immunol"},{"issue":"1","key":"690_CR16","first-page":"7","volume":"19","author":"AP Albino","year":"1998","unstructured":"Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: a molecular and cellular puzzle. Am J Otol. 1998;19(1):7\u201319.","journal-title":"Am J Otol"},{"issue":"4","key":"690_CR17","doi-asserted-by":"publisher","first-page":"E220","DOI":"10.1002\/lary.28084","volume":"130","author":"I Jovanovic","year":"2020","unstructured":"Jovanovic I, et al. Perimatrix of middle ear cholesteatoma: A granulation tissue with a specific transcriptomic signature. Laryngoscope. 2020;130(4):E220\u20137.","journal-title":"Laryngoscope"},{"issue":"5","key":"690_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10162-019-00727-1","volume":"20","author":"R Imai","year":"2019","unstructured":"Imai R, et al. Osteoclasts modulate bone erosion in cholesteatoma via RANKL signaling. J Assoc Res Otolaryngol. 2019;20(5):449\u201359.","journal-title":"J Assoc Res Otolaryngol"},{"issue":"5","key":"690_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/00129492-200209000-00007","volume":"23","author":"S Yetiser","year":"2002","unstructured":"Yetiser S, Satar B, Aydin N. Expression of epidermal growth factor, tumor necrosis factor-alpha, and interleukin-1alpha in chronic otitis media with or without cholesteatoma. Otol Neurotol. 2002;23(5):647\u201352.","journal-title":"Otol Neurotol"},{"issue":"7","key":"690_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3109\/00016480903413657","volume":"130","author":"T Helgaland","year":"2010","unstructured":"Helgaland T, et al. In vitro cholesteatoma growth and secretion of cytokines. Acta Otolaryngol. 2010;130(7):815\u20139.","journal-title":"Acta Otolaryngol"},{"key":"690_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/lary.24176","volume":"123 Suppl S5","author":"JD Macias","year":"2013","unstructured":"Macias JD, et al. Differential gene expression in cholesteatoma by DNA chip analysis. Laryngoscope. 2013;123 Suppl S5:S1-21.","journal-title":"Laryngoscope"},{"issue":"5","key":"690_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/00016480310015254","volume":"124","author":"R Naim","year":"2004","unstructured":"Naim R, et al. Co-expression of different angiogenic factors in external auditory canal cholesteatoma. Acta Otolaryngol. 2004;124(5):563\u20138.","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"690_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.LAB.0000050763.64145.CB","volume":"83","author":"T Yamamoto-Fukuda","year":"2003","unstructured":"Yamamoto-Fukuda T, et al. Possible involvement of keratinocyte growth factor and its receptor in enhanced epithelial-cell proliferation and acquired recurrence of middle-ear cholesteatoma. Lab Invest. 2003;83(1):123\u201336.","journal-title":"Lab Invest"},{"issue":"2","key":"690_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3109\/00016489.2013.847282","volume":"134","author":"MB Thorup","year":"2014","unstructured":"Thorup MB, et al. Expression of the epidermal growth factor system in human middle ear cholesteatoma. Acta Otolaryngol. 2014;134(2):124\u201334.","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"690_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S0022215119000112","volume":"133","author":"MA Hamed","year":"2019","unstructured":"Hamed MA, et al. Localisation of basic fibroblast growth factor in cholesteatoma matrix: an immunochemical study. J Laryngol Otol. 2019;133(3):183\u20136.","journal-title":"J Laryngol Otol"},{"issue":"1","key":"690_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/MLG.0b013e31814faafa","volume":"118","author":"MA Huisman","year":"2008","unstructured":"Huisman MA, et al. Transforming growth factor beta and wound healing in human cholesteatoma. Laryngoscope. 2008;118(1):94\u20138.","journal-title":"Laryngoscope"},{"key":"690_CR27","volume-title":"Cholesteatoma and ear surgery: an update","author":"H Takahashi","year":"2013","unstructured":"Takahashi H. Cholesteatoma and ear surgery: an update. Amsterdam: Kugler Publications; 2013."},{"issue":"7","key":"690_CR28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/MAO.0b013e3181ec1bb9","volume":"31","author":"F d'Alessandro","year":"2010","unstructured":"d\u2019Alessandro F, et al. Paracrine loops of keratinocyte stimulation in cholesteatoma tissue: an immunofluorescence, transmission electron microscopy, and molecular study. Otol Neurotol. 2010;31(7):1163\u20139.","journal-title":"Otol Neurotol"},{"issue":"2","key":"690_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/archotol.1996.01890140043009","volume":"122","author":"H Kojima","year":"1996","unstructured":"Kojima H, et al. Expression of messenger RNA for keratinocyte growth factor in human cholesteatoma. Arch Otolaryngol Head Neck Surg. 1996;122(2):157\u201360.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"3","key":"690_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10162-018-0662-z","volume":"19","author":"T Yamamoto-Fukuda","year":"2018","unstructured":"Yamamoto-Fukuda T, et al. Keratinocyte growth factor (KGF) modulates epidermal progenitor cell kinetics through activation of p63 in middle ear cholesteatoma. J Assoc Res Otolaryngol. 2018;19(3):223\u201341.","journal-title":"J Assoc Res Otolaryngol"},{"issue":"3","key":"690_CR31","first-page":"153","volume":"34","author":"L Presutti","year":"2014","unstructured":"Presutti L, et al. Results of endoscopic middle ear surgery for cholesteatoma treatment: a systematic review. Acta Otorhinolaryngol Ital. 2014;34(3):153\u20137.","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"3","key":"690_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1067\/mhn.2000.104666","volume":"123","author":"SE Stangerup","year":"2000","unstructured":"Stangerup SE, et al. Recurrence of attic cholesteatoma: different methods of estimating recurrence rates. Otolaryngol Head Neck Surg. 2000;123(3):283\u20137.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"7","key":"690_CR33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1017\/S0022215100130804","volume":"109","author":"E Vartiainen","year":"1995","unstructured":"Vartiainen E. Factors associated with recurrence of cholesteatoma. J Laryngol Otol. 1995;109(7):590\u20132.","journal-title":"J Laryngol Otol"},{"issue":"12","key":"690_CR34","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00405-008-0707-8","volume":"265","author":"A Mustafa","year":"2008","unstructured":"Mustafa A, et al. Complications of chronic otitis media with cholesteatoma during a 10-year period in Kosovo. Eur Arch Otorhinolaryngol. 2008;265(12):1477\u201382.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"690_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/archotol.132.7.734","volume":"132","author":"M Yoshikawa","year":"2006","unstructured":"Yoshikawa M, et al. Identification of specific gene expression profiles in fibroblasts derived from middle ear cholesteatoma. Arch Otolaryngol Head Neck Surg. 2006;132(7):734\u201342.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"690_CR36","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1038\/s41598-018-24616-4","volume":"8","author":"J Nagel","year":"2018","unstructured":"Nagel J, et al. Stem cells in middle ear cholesteatoma contribute to its pathogenesis. Sci Rep. 2018;8:6204.","journal-title":"Sci Rep"},{"issue":"2 Pt 1","key":"690_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00005537-199602000-00021","volume":"106","author":"J Bujia","year":"1996","unstructured":"Bujia J, et al. Quantitative analysis of interleukin-1-alpha gene expression in middle ear cholesteatoma. Laryngoscope. 1996;106(2 Pt 1):217\u201320.","journal-title":"Laryngoscope"},{"issue":"2","key":"690_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00418-012-0947-y","volume":"138","author":"S Raffa","year":"2012","unstructured":"Raffa S, et al. Cholesteatoma-associated fibroblasts modulate epithelial growth and differentiation through KGF\/FGF7 secretion. Histochem Cell Biol. 2012;138(2):251\u201369.","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"690_CR39","first-page":"1","volume":"62","author":"M Miyasato","year":"2013","unstructured":"Miyasato M, Takeno S, Hirakawa K. Expression of RANKL and proliferation abilities of cultured human middle ear cholesteatoma epithelial cells. Hiroshima J Med Sci. 2013;62(1):1\u20136.","journal-title":"Hiroshima J Med Sci"},{"issue":"2","key":"690_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00405-013-2402-7","volume":"271","author":"HY Lee","year":"2014","unstructured":"Lee HY, et al. Expression of pattern recognition receptors in cholesteatoma. Eur Arch Otorhinolaryngol. 2014;271(2):245\u201353.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"690_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00405-006-0030-1","volume":"263","author":"M Szczepanski","year":"2006","unstructured":"Szczepanski M, et al. Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma. Eur Arch Otorhinolaryngol. 2006;263(7):603\u20137.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5","key":"690_CR42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/00129492-200309000-00002","volume":"24","author":"FA Peek","year":"2003","unstructured":"Peek FA, et al. Lipopolysaccharide concentration and bone resorption in cholesteatoma. Otol Neurotol. 2003;24(5):709\u201313.","journal-title":"Otol Neurotol"},{"issue":"4","key":"690_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1471-4906(01)01863-4","volume":"22","author":"CD Buckley","year":"2001","unstructured":"Buckley CD, et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 2001;22(4):199\u2013204.","journal-title":"Trends Immunol"},{"issue":"1","key":"690_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/cells9010199","volume":"9","author":"M Sch\u00fcrmann","year":"2020","unstructured":"Sch\u00fcrmann M, et al. Stem cell-induced inflammation in cholesteatoma is inhibited by the TLR4 Antagonist LPS-RS. Cells. 2020;9(1):199.","journal-title":"Cells"},{"issue":"7677","key":"690_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature24271","volume":"550","author":"S Naik","year":"2017","unstructured":"Naik S, et al. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature. 2017;550(7677):475\u201380.","journal-title":"Nature"},{"issue":"5","key":"690_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1524-475X.2008.00410.x","volume":"16","author":"S Barrientos","year":"2008","unstructured":"Barrientos S, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585\u2013601.","journal-title":"Wound Repair Regen"},{"issue":"4","key":"690_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00408-004-2534-z","volume":"183","author":"M Hetzel","year":"2005","unstructured":"Hetzel M, et al. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005;183(4):225\u201337.","journal-title":"Lung"},{"issue":"2","key":"690_CR48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1046\/j.1523-1755.2001.059002579.x","volume":"59","author":"F Strutz","year":"2001","unstructured":"Strutz F, et al. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int. 2001;59(2):579\u201392.","journal-title":"Kidney Int"},{"issue":"10","key":"690_CR49","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1163\/092050611X580463","volume":"23","author":"A Yu","year":"2012","unstructured":"Yu A, et al. Effect of EGF and bFGF on fibroblast proliferation and angiogenic cytokine production from cultured dermal substitutes. J Biomater Sci Polym Ed. 2012;23(10):1315\u201324.","journal-title":"J Biomater Sci Polym Ed"},{"issue":"3","key":"690_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1096\/fj.03-0699com","volume":"18","author":"GR Grotendorst","year":"2004","unstructured":"Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 2004;18(3):469\u201379.","journal-title":"FASEB J"},{"issue":"8","key":"690_CR51","first-page":"1743","volume":"63","author":"C Lindvall","year":"2003","unstructured":"Lindvall C, et al. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res. 2003;63(8):1743\u20137.","journal-title":"Cancer Res"},{"issue":"13","key":"690_CR52","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.1074\/jbc.270.13.7495","volume":"270","author":"H Toyoda","year":"1995","unstructured":"Toyoda H, et al. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem. 1995;270(13):7495\u2013500.","journal-title":"J Biol Chem"},{"issue":"2","key":"690_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2334\/josnusd.47.105","volume":"47","author":"N Sato","year":"2005","unstructured":"Sato N, et al. The effect of IL-1alpha and nifedipine on cell proliferation and DNA synthesis in cultured human gingival fibroblasts. J Oral Sci. 2005;47(2):105\u201310.","journal-title":"J Oral Sci"},{"issue":"4","key":"690_CR54","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.4049\/jimmunol.172.4.2668","volume":"172","author":"MA Olman","year":"2004","unstructured":"Olman MA, et al. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol. 2004;172(4):2668\u201377.","journal-title":"J Immunol"},{"issue":"4","key":"690_CR55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/34.4.321","volume":"34","author":"M Mihara","year":"1995","unstructured":"Mihara M, et al. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol. 1995;34(4):321\u20135.","journal-title":"Br J Rheumatol"},{"issue":"5","key":"690_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0024-3205(98)00281-1","volume":"63","author":"L Postiglione","year":"1998","unstructured":"Postiglione L, et al. Expression of GM-CSF receptor and \u201cin vitro\u201d effects of GM-CSF on human fibroblasts. Life Sci. 1998;63(5):327\u201336.","journal-title":"Life Sci"},{"issue":"2","key":"690_CR57","first-page":"196","volume":"66","author":"BD Gitter","year":"1989","unstructured":"Gitter BD, et al. Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha. Immunology. 1989;66(2):196\u2013200.","journal-title":"Immunology"},{"issue":"2","key":"690_CR58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jcp.1041440219","volume":"144","author":"C Marchese","year":"1990","unstructured":"Marchese C, et al. Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J Cell Physiol. 1990;144(2):326\u201332.","journal-title":"J Cell Physiol"},{"issue":"4","key":"690_CR59","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3727\/000000002783985819","volume":"11","author":"KE Hamoen","year":"2002","unstructured":"Hamoen KE, Morgan JR. Transient hyperproliferation of a transgenic human epidermis expressing hepatocyte growth factor. Cell Transplant. 2002;11(4):385\u201395.","journal-title":"Cell Transplant"},{"issue":"1","key":"690_CR60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.exer.2005.10.033","volume":"83","author":"R Yanai","year":"2006","unstructured":"Yanai R, et al. Correlation of proliferative and anti-apoptotic effects of HGF, insulin, IGF-1, IGF-2, and EGF in SV40-transformed human corneal epithelial cells. Exp Eye Res. 2006;83(1):76\u201383.","journal-title":"Exp Eye Res"},{"issue":"5","key":"690_CR61","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0092-8674(00)00178-1","volume":"103","author":"A Szabowski","year":"2000","unstructured":"Szabowski A, et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell. 2000;103(5):745\u201355.","journal-title":"Cell"},{"issue":"2","key":"690_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3342\/ceo.2008.1.2.86","volume":"1","author":"AM Raynov","year":"2008","unstructured":"Raynov AM, et al. Establishment and characterization of an in vitro model for cholesteatoma. Clin Exp Otorhinolaryngol. 2008;1(2):86\u201391.","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"10","key":"690_CR63","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s00405-014-3237-6","volume":"272","author":"T Yamamoto-Fukuda","year":"2015","unstructured":"Yamamoto-Fukuda T, et al. In vivo over-expression of KGF mimic human middle ear cholesteatoma. Eur Arch Otorhinolaryngol. 2015;272(10):2689\u201396.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"690_CR64","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MAO.0b013e318181337f","volume":"29","author":"Y Mishiro","year":"2008","unstructured":"Mishiro Y, et al. The investigation of the recurrence rate of cholesteatoma using Kaplan\u2013Meier survival analysis. Otol Neurotol. 2008;29(6):803\u20136.","journal-title":"Otol Neurotol"},{"issue":"2","key":"690_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00016489609137844","volume":"116","author":"W Kuijpers","year":"1996","unstructured":"Kuijpers W, et al. Squamous metaplasia of the middle ear epithelium. Acta Otolaryngol. 1996;116(2):293\u20138.","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"690_CR66","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00109-014-1217-3","volume":"93","author":"MJ Szczepanski","year":"2015","unstructured":"Szczepanski MJ, et al. Molecular signaling of the HMGB1\/RAGE axis contributes to cholesteatoma pathogenesis. J Mol Med (Berl). 2015;93(3):305\u201314.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"690_CR67","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3109\/00016489609137917","volume":"116","author":"V Schilling","year":"1996","unstructured":"Schilling V, et al. Overexpression of tenascin in cholesteatoma and external auditory meatal skin compared to retroauricular epidermis. Acta Otolaryngol. 1996;116(5):741\u20136.","journal-title":"Acta Otolaryngol"},{"key":"690_CR68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40463-015-0104-4","volume":"44","author":"DR Randall","year":"2015","unstructured":"Randall DR, Park PS, Chau JK. Identification of altered protein abundances in cholesteatoma matrix via mass spectrometry-based proteomic analysis. J Otolaryngol Head Neck Surg. 2015;44:50.","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"1","key":"690_CR69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0194-5998(96)70287-5","volume":"114","author":"H Shinoda","year":"1996","unstructured":"Shinoda H, Huang CC. Heat shock proteins in middle ear cholesteatoma. Otolaryngol Head Neck Surg. 1996;114(1):77\u201383.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"690_CR70","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/MAO.0b013e31819fe6ed","volume":"30","author":"A Juhasz","year":"2009","unstructured":"Juhasz A, et al. Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas. Otol Neurotol. 2009;30(4):559\u201365.","journal-title":"Otol Neurotol"},{"issue":"1","key":"690_CR71","first-page":"26","volume":"19","author":"MA Arriaga","year":"1998","unstructured":"Arriaga MA, Dixon P. Cytotoxicity of cytokeratin monoclonal antibody against keratinocytes: a possible therapeutic adjunct for cholesteatoma? Am J Otol. 1998;19(1):26\u20139.","journal-title":"Am J Otol"},{"issue":"1","key":"690_CR72","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MAO.0000000000000590","volume":"36","author":"MB Gluth","year":"2015","unstructured":"Gluth MB, et al. Immunotargeted photodynamic therapy for cholesteatoma: in vitro results with anti-EGFR-coated indocyanine green nanocapsules. Otol Neurotol. 2015;36(1):76\u201381.","journal-title":"Otol Neurotol"},{"issue":"8","key":"690_CR73","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/MAO.0000000000002297","volume":"40","author":"A Kara","year":"2019","unstructured":"Kara A, et al. Evaluation of the effect of diclofenac sodium and 5-fluourasil in a 3D cholesteatoma cell culture model. Otol Neurotol. 2019;40(8):1018\u201325.","journal-title":"Otol Neurotol"},{"issue":"3","key":"690_CR74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0196-0709(91)90142-3","volume":"12","author":"CG Wright","year":"1991","unstructured":"Wright CG, Bird LL, Meyerhoff WL. Effect of 5-fluorouracil in cholesteatoma development in an animal model. Am J Otolaryngol. 1991;12(3):133\u20138.","journal-title":"Am J Otolaryngol"},{"issue":"6","key":"690_CR75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/014556139407300613","volume":"73","author":"DT Sala","year":"1994","unstructured":"Sala DT. Topical applications of 5-fluorouracil in the medical treatment of cholesteatoma of the middle ear. Ear Nose Throat J. 1994;73(6):412\u20134.","journal-title":"Ear Nose Throat J"},{"issue":"4","key":"690_CR76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.anl.2005.05.015","volume":"32","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, et al. Clinical efficacy of 5-fluorouracil (5-FU) topical cream for treatment of cholesteatoma. Auris Nasus Larynx. 2005;32(4):353\u20137.","journal-title":"Auris Nasus Larynx"},{"issue":"10","key":"690_CR77","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00405-008-0597-9","volume":"265","author":"T Yamamoto-Fukuda","year":"2008","unstructured":"Yamamoto-Fukuda T, et al. Topical application of 5-fluorouracil on attic cholesteatoma results in downregulation of keratinocyte growth factor and reduction of proliferative activity. Eur Arch Otorhinolaryngol. 2008;265(10):1173\u20138.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5","key":"690_CR78","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/00129492-200109000-00002","volume":"22","author":"BI Nageris","year":"2001","unstructured":"Nageris BI, Grushko I, Feinmesser R. Cholesteatoma prevention by local treatment with vitamin A. Otol Neurotol. 2001;22(5):576\u20138.","journal-title":"Otol Neurotol"},{"issue":"11","key":"690_CR79","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/jama.2013.2194","volume":"309","author":"SM Opal","year":"2013","unstructured":"Opal SM, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154\u201362.","journal-title":"JAMA"},{"issue":"8","key":"690_CR80","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","volume":"38","author":"TW Rice","year":"2010","unstructured":"Rice TW, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38(8):1685\u201394.","journal-title":"Crit Care Med"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-020-00690-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12964-020-00690-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-020-00690-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T02:23:09Z","timestamp":1634350989000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-020-00690-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1186\/s12964-020-00690-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-74086\/v1","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"10 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The samples were obtained after fully informed and written consent prior to surgery according to local and international guidelines and all clinical investigations were ethically approved (Reg. no. 2235) and conducted according to the principles of the Declaration of Helsinki (1964) and local guidelines (Bezirksregierung Detmold\/M\u00fcnster).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}